Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy.

However, patients with high baseline levels of PD‐L2 on plasma EVs showed a trend toward shorter PFS (1.9 vs. 7.7 months, HR = 1.59, p = 0.3069; Figure 3c ) compared to those with low levels, while OS was not significantly different (14.9 vs. 19.2 months, HR = 0.90, p = 0.8431; Figure 3d ).

also in 53,322 other papers

However, an increasing trend in EV membrane protein expression was observed in most patients who attained PR and in some with SD after treatment, as indicated by the post‐treatment time point and the change levels between baseline and post‐treatment (Figure 2b,c ).

also in 63,971 other papers